Nephrocare health services limited IPO Overview
Nephrocare health services limited IPO is a Mainboard public issue offered through a Book Building issue with a total issue size of ₹871.05 Cr. The IPO price band is set at ₹438 to ₹460 per share, and retail investors can apply with a minimum investment of ₹14,720 as per IPO guidelines.
The Nephrocare health services limited IPO opens on 10 Dec 2025 and closes on 12 Dec 2025. The IPO allotment is expected to be finalized on 15 Dec 2025, and the equity shares are proposed to be listed on BSE,NSE on 17 Dec 2025.
Investors can refer to the Nephrocare health services limited IPO RHP-DRHP for detailed information. The issue is managed by ICICI Securities Ltd.,Ambit Pvt.Ltd.,IIFL Capital Services Ltd.,Nomura Financial Advisory,Securities (India) Pvt.Ltd. as the book running lead manager, while Kfin Technologies Limited is the registrar to the IPO. Before investing, market participants often review IPO details, valuation, PE ratio, financials, and risk factors.
About nephrocare health services limited
As of Sep 30, 2025, Nephrocare operated 519 clinics with 51 across the Philippines, Uzbekistan, and Nepal. This includes the world’s largest dialysis clinic in Uzbekistan. In India, the company had a presence across 288 cities in 21 States and 4 Union Territories. Approximately 77.53% of its clinics were located in tier II and tier III cities, addressing a critical need in underserved regions.
During Fiscal 2025, Nephrocare served 29,281 patients and completed 2,885,450 dialysis treatments, accounting for roughly 10% of the country's total dialysis patient base. Additionally, by Sep 30, it has served 31,046 patients and completed 1,591,377 treatments in India. As of Sep 30, 2025, the company has 5,562 dialysis machines.
Nephrocare has formed strategic partnerships with established hospital chains such as Max Super Speciality Hospital, Fortis Escorts Hospitals, Care Hospitals, Wockhardt Hospitals, Paras Healthcare, The Calcutta Medical Research Institute, Jehangir Hospital, and Ruby Hall Clinic to operate in-house dialysis centers.
Competitive strengths
India’s and Asia’s largest dialysis chain with leadership across our markets
Scale coupled with asset-light model driving cost efficiencies and operational excellence
Driving clinical excellence and quality through protocols and advanced technology
Organic growth augmented by proven track record of acquisitions and integration in India and internationally
Patient-centric leadership and seasoned management team backed by marquee investors
Driving sustainable dialysis leadership with environmental, social and governance measures
Track record of sustainable growth, profitability and return
Investment Objective
Pre-payment, or scheduled repayment, in full or part, of certain borrowings availed by the Company
General corporate purposes